Effect of Telmisartan on Renal Outcomes
Annals of Internal MedicinePublished 7 July 2009
Johannes F.E. Mann, Roland E. Schmieder, Leanne Dyal, Matthew J. McQueen, Helmut Schumacher, Janice Pogue
Citations193
SJR quartileQ1
SJR score3.38
SNIP3.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The effects of telmisartan on renal function in a large sample that was intolerant of ACE inhibitors and had vascular disease but not macroalbuminuria are examined, and the composite renal outcome was dialysis or doubling of serum creatinine.
Abstract
In adults with vascular disease but without macroalbuminuria, the effects of telmisartan on major renal outcomes were similar to those of placebo.
Keywords
Medicine
New England Journal of MedicineEffects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
7,484 Citations2001Barry M. Brenner, Mark E. Cooper +8 more
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
New England Journal of MedicineRenoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
5,920 Citations2001Edmund J. Lewis, Lawrence G. Hunsicker +8 more
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
New England Journal of MedicineTelmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
3,484 Citations2008The ONTARGET Investigators
Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema and a increased risk of hypotensive symptoms.
The LancetEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
3,195 Citations2000
Ramipril was beneficial for cardiovascular events and overt nephropathy in people with diabetes and the cardiovascular benefit was greater than that attributable to the decrease in blood pressure.
New England Journal of MedicineAssessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
2,908 Citations2006Lesley A. Stevens, Josef Coresh +2 more
Current methods of measuring GFR and GFR-estimating equations and their strengths and weaknesses as applied to chronic kidney disease are considered.
The LancetOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2,537 Citations2004Stevo Julius, Sverre E. Kjeldsen +12 more
Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period, which emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.
PubMedEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
2,103 Citations2000Jfe Mann, Hertzel C. Gerstein +1 more
The LancetRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
1,580 Citations2008Johannes F.E. Mann, Roland E. Schmieder +17 more
In people at high vascular risk, telmisartan's effects on major renal outcomes are similar to ramipril, and although combination therapy reduces proteinuria to a greater extent than monotherapy, overall it worsens major renal outcome.
Annals of Internal MedicineProgression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
1,143 Citations2003Tazeen H. Jafar, Paul C. Stark +9 more
This meta-analysis showed that systolic blood pressure and urinary protein excretion were related to the risk for renal disease progression in patients with nondiabetic kidney disease.
New England Journal of MedicinePreventing Microalbuminuria in Type 2 Diabetes
1,020 Citations2004Piero Ruggenenti, Anna Fassi +15 more
In subjects with type 2 diabetes and hypertension but with normoalbuminuria, the use of trandolapril plus verapamil and trandOLapril alone decreased the incidence of micro Albuminuria to a similar extent to that of placebo.
The LancetEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
994 Citations2008‡
Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke.
Archives of Internal MedicineAngiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine
795 Citations2000George L. Bakris, Matthew R. Weir
A strong association exists between acute increases in serum creatinine of up to 30% that stabilize within the first 2 months of ACEI therapy and long-term preservation of renal function and withdrawal of an ACEI in patients with preexisting renal insufficiency is recommended.
Annals of Internal MedicineMeta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
712 Citations2008Regina Kunz, Chris Friedrich +2 more
A systematic review and meta-analysis of the effects of ARBs on urinary protein excretion in patients with nephropathy compared with placebo and other antihypertensive agents and their combinations showed that ARBs delay progression of proteinuria over the short (1 to 4 months) and longer (5 to 12 months) terms.
Journal of Clinical InvestigationMechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
617 Citations2006Giuseppe Remuzzi
American Heart JournalRationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
382 Citations2004Koon Teo
The Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (TRANSCEND) will determine if tel Misartan is superior to placebo in patients who are intolerant of ACE inhibitors.
Annals of Internal MedicineSystematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension
349 Citations2008David B. Matchar, Douglas C McCrory +7 more
This systematic review of trials that directly compared ACE inhibitors and ARBs in adults with essential hypertension found good evidence that the agents had similar long-term effects on blood pressure, and cough was more frequent with ACE inhibitors than ARBs.
Archives of Internal MedicineThe Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease
295 Citations2005Janice P. Lea
Baseline proteinuria and GFR predicted the rgate of GFR decline and initial change in proteinuria from baseline to 6 months predicted subsequent progression, with this relationship extending to participants with baseline urinary protein levels less than 300 mg/d.
Kidney InternationalA short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function
207 Citations1997Alfred J. Apperloo, Dick de Zeeuw +1 more
An initial fall in GFR after starting antihypertensive treatment in patients with a mild to moderate renal function impairment is reversible even after years of treatment, suggesting that this therapy-induced fall is of hemodynamic and not of structural origin.
Archives of Internal MedicineAdverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction
186 Citations2007Christopher O. Phillips, Amir Kashani +3 more
Combination ARB plus ACE inhibitor vs control treatment that included ACE inhibitors was associated with significant increases in medication discontinuations because of adverse effects in patients with chronic heart failure and symptomatic left ventricular dysfunction, and marked increases in adverse effects.
American Journal of Kidney DiseasesChronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
175 Citations2000Piero Ruggenenti, Annalisa Perna +3 more
The Ramipril Efficacy in Nephropathy study found that angiotensin-converting enzyme (ACE) inhibitors effectively decreased proteinuria, glomerular filtration rate (GFR) decline (DeltaGFR), and incidence of end-stage renal disease (ESRD) in patients with proteinuric chronic nephropathies.
American Journal of Kidney DiseasesProgression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study
85 Citations2003Johannes F.E. Mann, Hertzel C. Gerstein +6 more
American Journal of Kidney DiseasesExploring the Differences in Epidemiology of Treated ESRD Between Germany and England and Wales
51 Citations2006Fergus Caskey, Hans-Jürgen Schober-Halstenberg +5 more
Much of the difference in RRT incidence between Germany and E&W is explained by a greater prevalence of diabetes, hypertension, and vascular disease in the German general population, particularly those older than 65 years, and lower competing mortality risk.
Nephrology Dialysis TransplantationAnnual report of the German renal registry 1998
50 Citations1999Ulrich Frei
During the past 3 years, the basis of a German Renal Registry has been established and an agreement between end-stage renal disease (ESRD) therapy providers, insurance companies and the government has been reached to fund and support the registry office and its electronic data base.
Journal of Vascular SurgeryTelmisartan, ramipril, or both in patients at high risk for vascular events
32 Citations2008